Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.
Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna reinforce the utility of the Oncotype DX Breast Recurrence...
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ON Semiconductor Corporation...
- Real-world evidence reinforces TAILORx treatment paradigm and standard of care use for Oncotype DX((R)) test
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
Genomic Health I (NASDAQ:GHDX) traded in a range yesterday that spanned from a low of $74.01 to a high of $76.76. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of...
Esperion Therapeutics (ESPR) generates no revenues in the fourth quarter. The company provides guidance for 2019.
Spectrum Pharma (SPPI) misses bottom-line estimates in the fourth quarter but beats on revenues.
Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.
Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.
Genomic Health (GHDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genomic Health I (NASDAQ:GHDX) traded in a range yesterday that spanned from a low of $75.37 to a high of $86.60. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of...
Diagnostic Solutions Laboratory (DSL) continues its innovative vision to transform and improve personalized medicine by introducing its first DNA SNP test, GenomicInsight(TM) Genomic Health Profile powered...
Genomic Health (GHDX) delivered earnings and revenue surprises of 6.67% and 2.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif. (AP) _ Genomic Health Inc. (GHDX) on Wednesday reported fourth-quarter net income of $8.9 million.
Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2018.
The "Liquid Biopsy Market, Global Analysis by Cancer, Product, Circulating Biomarkers, Clinical Application, Regions, and Companies" report has been added to ResearchAndMarkets.com's offering.
Genomic Health (GHDX) is expected to gain from higher Oncotype DX breast cancer test revenues in Q4.
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end...